Recent News

• 03.10.2025 - New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
• 02.25.2025 - LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer
• 02.13.2025 - LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
• 02.11.2025 - LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
• 02.10.2025 - LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

Recent Filings

• 02.25.2025 - EX-99.1 EX-99.1
• 02.25.2025 - 8-K Current report
• 02.21.2025 - 8-K Current report
• 02.18.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.18.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.13.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.13.2025 - 8-K Current report
• 02.13.2025 - EX-99.1 EX-99.1
• 02.12.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.10.2025 - RW Registration Withdrawal Request